BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1025 related articles for article (PubMed ID: 15879764)

  • 1. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
    Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
    J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in renal cell carcinoma.
    Shuch BM; Lam JS; Belldegrun AS; Figlin RA
    Semin Oncol; 2006 Oct; 33(5):563-75. PubMed ID: 17045085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma.
    Lam JS; Breda A; Belldegrun AS; Figlin RA
    J Clin Oncol; 2006 Dec; 24(35):5565-75. PubMed ID: 17158542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors and selection for clinical studies of patients with kidney cancer.
    Lam JS; Klatte T; Kim HL; Patard JJ; Breda A; Zisman A; Pantuck AJ; Figlin RA
    Crit Rev Oncol Hematol; 2008 Mar; 65(3):235-62. PubMed ID: 17931881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy.
    Lam JS; Belldegrun AS; Figlin RA
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6304S-9S. PubMed ID: 15448022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic factors in renal cell carcinoma].
    Letang N; Cabaniols L; Pouessel D; Robert M; Iborra F; Culine S; Patard JJ; Guiter J; Thuret R
    Bull Cancer; 2009 Apr; 96(4):475-84. PubMed ID: 19357021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of adjuvant therapy in non-metastatic RCC.
    Bleumer I; de Mulder PH; Mulders PF
    Can J Urol; 2006 Apr; 13 Suppl 2():57-62. PubMed ID: 16672131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The staging of renal cell carcinoma.
    Shuch B; La Rochelle JC; Pantuck AJ; Belldegrun AS
    Curr Opin Urol; 2008 Sep; 18(5):455-61. PubMed ID: 18670267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review.
    Sun M; Shariat SF; Cheng C; Ficarra V; Murai M; Oudard S; Pantuck AJ; Zigeuner R; Karakiewicz PI
    Eur Urol; 2011 Oct; 60(4):644-61. PubMed ID: 21741163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of gene expression analysis of renal cell carcinoma.
    Leppert JT; Pantuck AJ
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):293-9. PubMed ID: 16445381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic markers in renal cell carcinoma.
    Ljungberg B
    Curr Opin Urol; 2007 Sep; 17(5):303-8. PubMed ID: 17762621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers.
    Minervini A; Di Cristofano C; Gacci M; Serni S; Menicagli M; Lanciotti M; Salinitri G; Rocca CD; Lapini A; Nesi G; Bevilacqua G; Minervini R; Carini M
    J Urol; 2008 Oct; 180(4):1284-9. PubMed ID: 18707725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal cell carcinoma: current status and emerging therapies.
    Nelson EC; Evans CP; Lara PN
    Cancer Treat Rev; 2007 May; 33(3):299-313. PubMed ID: 17329029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant interferon alpha therapy in renal cell carcinoma (RCC): prognostic value of DNA cytophotometry.
    Basting R; Corvin S; Händel D; Hinke A; Schmidt D
    Anticancer Res; 1999; 19(2C):1493-5. PubMed ID: 10365130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in clear cell renal cell carcinoma.
    George S; Bukowski RM
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1737-47. PubMed ID: 18062748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
    Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
    Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
    Homicsko K; Berthold DR
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S4-8. PubMed ID: 21173604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staging refinements in renal cell carcinoma.
    Howard GE; Wood CG
    Curr Opin Urol; 2006 Sep; 16(5):317-20. PubMed ID: 16905974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
    Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
    Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. pT1 substaging in renal cell carcinoma: validation of the 2002 TNM staging modification of malignant renal epithelial tumors.
    Salama ME; Guru K; Stricker H; Peterson E; Peabody J; Menon M; Amin MB; De Peralta-Venturina M
    J Urol; 2005 May; 173(5):1492-5. PubMed ID: 15821466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.